Drug class
Calcitonin gene-related peptide (CGRP) ligand inhibitor; humanised monoclonal antibody
Mechanism of action
Binds CGRP ligand and prevents its interaction with the CGRP receptor, inhibiting a pathway involved in migraine pathophysiology.
General use cases
- Preventive treatment of migraine in adults; administered by intravenous infusion every three months under the product label, not for acute treatment of migraine attacks
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
